Incorrect password
evipedia.ai Suggest Edit

Cordiart for Health & Longevity

Evidence Review created on 05/07/2026 using AI4L / Opus 4.7

Also known as: Lycomato Tomato Extract, Standardized Tomato Nutrient Complex

Motivation

Cordiart is a nutraceutical based on a standardized extract of ripe tomato fruit, sold primarily in Europe as a food supplement for heart and circulation support. Its central active fraction is a tomato oleoresin containing the carotenoid lycopene together with related plant pigments and natural fats. Interest in this matrix comes from observational data linking high tomato and lycopene intake to lower risk of heart-related events.

The product is a successor to earlier tomato-derived ingredients, including a dried tomato concentrate that received a qualified European regulatory opinion for healthy blood flow. Headline data for related extracts have shown modest but reproducible signals on the health of blood vessel walls and on blood pressure.

This review examines the composition, mechanism, clinical evidence, expected benefits, potential risks, interactions, and practical use considerations for Cordiart as a longevity-oriented intervention. It identifies where the supporting evidence is strong, where it is mechanistic only, and where it is contested.

Benefits - Risks - Protocol - Conclusion

This section presents general-audience overviews of Cordiart and the underlying tomato carotenoid matrix from health-focused experts and publications.

Note: Cordiart is a regional brand, and expert coverage by name is sparse. The above selection prioritizes coverage of the underlying standardized tomato extract / lycopene matrix that defines the product. Only four items are listed because no verifiable, directly relevant carotenoid- or lycopene-focused post by Peter Attia (peterattiamd.com) or Andrew Huberman (hubermanlab.com) could be confirmed at the time of authoring.

Grokipedia

No dedicated Grokipedia article was found for Cordiart as of 05/07/2026.

Examine

No dedicated Examine article was found for Cordiart as of 05/07/2026.

ConsumerLab

No dedicated ConsumerLab review was found for Cordiart as of 05/07/2026.

Systematic Reviews

This section lists the most relevant recent systematic reviews and meta-analyses that bear on Cordiart’s principal active fraction (standardized tomato extract / lycopene).

Mechanism of Action

Cordiart’s biological activity derives from the synergy of lycopene with other tomato-derived phytonutrients (phytoene, phytofluene, beta-carotene, tocopherols, phytosterols) rather than lycopene alone. The proposed mechanisms include:

  • Antioxidant capacity: Lycopene has one of the highest singlet oxygen quenching constants among biological carotenoids and reduces lipid peroxidation, particularly of low-density lipoprotein (LDL, the cholesterol-carrying particle most associated with atherogenesis, the formation of fatty plaques inside artery walls). This decreases oxidized-LDL (oxLDL), a primary atherogenic species.

  • Endothelial function: In vitro and in vivo data suggest lycopene increases nitric oxide (NO) bioavailability and reduces NADPH oxidase activity in endothelial cells, improving flow-mediated dilation (FMD, an ultrasound measure of artery responsiveness).

  • Platelet aggregation: Aqueous tomato fractions (the lineage from which Cordiart’s matrix descends) inhibit ADP- and collagen-induced platelet aggregation through cyclic adenosine monophosphate (cAMP, an intracellular signal molecule) elevation and adenosine diphosphate (ADP) receptor antagonism.

  • Inflammation modulation: Lycopene downregulates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB, a master inflammatory transcription factor) signaling, reducing tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) expression.

  • Lipid metabolism: Phytosterols compete with cholesterol for micellar incorporation in the gut, modestly reducing cholesterol absorption.

Competing perspectives exist on the relative contribution of lycopene versus the broader phytonutrient matrix. Some authors argue that isolated lycopene supplementation produces inconsistent clinical results (e.g., in two large RCTs, only the trial using the whole tomato matrix showed FMD improvement), suggesting that the food-matrix or oleoresin form is mechanistically distinct from purified crystalline lycopene.

Pharmacological properties: Lycopene is a lipophilic carotenoid with elimination half-life estimated at 2–3 days; absorption is enhanced by dietary fat and by heat-disrupted plant matrices. Tissue distribution is highest in adipose, testes, adrenal glands, and prostate. Metabolism proceeds via the carotenoid 9’,10’-monooxygenase (BCO2, an enzyme that cleaves carotenoids into smaller bioactive metabolites) to apo-lycopenoids, and minor pathways involve cytochrome P450 (CYP) enzymes.

Historical Context & Evolution

Tomato consumption has been associated with cardiovascular benefit in epidemiological literature since the Mediterranean diet cohorts of the 1950s–1970s. Standardized tomato extracts emerged as a research category in the late 1990s when Israeli, Spanish, and Italian groups began characterizing oleoresin fractions enriched in lycopene plus colorless carotenoids (phytoene and phytofluene).

A key inflection occurred in 2009 when the European Food Safety Authority (EFSA) issued a qualified positive opinion on a water-soluble tomato concentrate (a relative of the lipophilic Cordiart matrix) for “helping maintain normal platelet aggregation, contributing to healthy blood flow,” — one of the few EFSA-approved cardiovascular health claims for a botanical extract.

Subsequent randomized trials (2010s) tested lipophilic standardized tomato extracts on blood pressure, endothelial function, and oxidative stress. Findings have been mixed: some trials showed clear improvements in flow-mediated dilation in patients with cardiovascular disease, while parallel trials in healthier or younger cohorts showed null effects on the same endpoint. Reasons proposed for the discrepancy include baseline endothelial function (greater room for improvement in compromised vessels), oxidative stress level, dose, duration, and the specific extract used. Several pivotal trials of lipophilic tomato extracts were sponsored by, or used materials supplied by, the ingredient manufacturer LycoRed (the developer of the Lyc-O-Mato matrix that underlies Cordiart) — a direct financial conflict of interest that should be considered when weighing the evidence base.

The current scientific picture is not a settled consensus: the cardiovascular signal is reproducible in higher-risk populations but inconsistent in primary-prevention populations, and the question of whether lycopene as a single molecule is the active principle, or whether the full matrix is required, remains open.

Expected Benefits

A dedicated search of clinical trial registries, meta-analyses, and expert reviews of Cordiart and its standardized tomato extract / lycopene matrix was performed before authoring this section.

Medium 🟩 🟩

Improvement in Endothelial Function

Standardized tomato extracts have been shown in multiple randomized trials to improve flow-mediated dilation (FMD), an ultrasound-based measure of artery responsiveness, particularly in adults with established cardiovascular disease or elevated cardiovascular risk. The proposed mechanism is increased nitric oxide bioavailability and reduced oxidative inactivation of NO. Evidence comes from several small-to-medium RCTs and is broadly supported by meta-analytic synthesis of lycopene and tomato extract trials. Effects are smaller and inconsistent in healthy normotensive populations.

Magnitude: Approximately 1.5–3.0 absolute percentage point increase in FMD in cardiovascular disease (CVD) or high-risk populations; effect smaller or absent in primary prevention cohorts.

Reduction in Oxidized LDL

Lycopene-enriched extracts consistently reduce circulating oxLDL, a marker of LDL particle modification implicated in atherogenesis. Meta-analyses of supplementation trials report a reproducible reduction across populations, with the effect proportional to baseline oxidative stress. The mechanism is direct singlet-oxygen quenching and protection of LDL-resident polyunsaturated fatty acids.

Magnitude: Approximately 10–20% reduction in oxLDL across pooled trials.

Low 🟩

Modest Reduction in Systolic Blood Pressure ⚠️ Conflicted

Several meta-analyses of lycopene and tomato extract supplementation suggest a small reduction in systolic blood pressure, more pronounced in hypertensive participants and at higher doses (>12 mg/day lycopene equivalent). The effect on diastolic blood pressure is less consistent. The discrepancy across trials likely reflects differences in baseline blood pressure, study population, and form of intervention (purified lycopene vs. tomato matrix). Trials in normotensive populations frequently show no effect, while trials enriched for hypertension show statistically significant reductions.

Magnitude: Approximately 3–5 mmHg reduction in systolic blood pressure (BP) in hypertensive adults; null effect in normotensive populations.

Modest LDL-C Reduction

Some randomized trials and meta-analyses report a small reduction in LDL cholesterol with lycopene-rich tomato extract supplementation, possibly mediated by phytosterol content and modulation of HMG-CoA reductase activity. The effect size is smaller than that of dietary phytosterol supplements at typical clinical doses.

Magnitude: Approximately 5–10 mg/dL reduction in LDL-C in pooled trials; not consistent across all studies.

Reduction in Platelet Aggregation

The water-soluble tomato concentrate that received an EFSA-qualified claim demonstrated reduced ex-vivo platelet aggregation in healthy adults. The lipophilic Cordiart matrix shares some bioactives but is not identical; data specifically for the lipophilic form are more limited.

Magnitude: Approximately 10–20% reduction in ex-vivo ADP- or collagen-induced platelet aggregation, demonstrated primarily for water-soluble tomato concentrate.

Speculative 🟨

Reduction in Cardiovascular Event Risk

Observational data link higher dietary and circulating lycopene to lower incidence of cardiovascular events and mortality. No randomized trial has demonstrated event reduction with Cordiart or any standardized tomato extract; the inference rests on surrogate endpoints (FMD, BP, oxLDL) and observational epidemiology. Confounding by overall dietary pattern is plausible.

Prostate Health Support

Higher lycopene intake is associated with reduced prostate cancer incidence in observational studies, with a modest dose-response. Randomized trials of lycopene as a single agent have been mixed or null. No prostate-specific trial has been conducted with Cordiart.

Skin Photoprotection

Lycopene increases minimal erythema dose under ultraviolet radiation and reduces sunburn redness in small trials of tomato paste or lycopene supplements. The effect on long-term skin aging or photodamage is mechanistic and inferred only.

Benefit-Modifying Factors

  • Baseline cardiovascular risk: Trial-level effects on flow-mediated dilation and blood pressure are larger in adults with established cardiovascular disease, hypertension, or metabolic syndrome than in healthy normotensive adults. Those with lower baseline endothelial function appear to benefit more.

  • Baseline lycopene status: Adults with low circulating lycopene at study entry tend to show larger biomarker shifts. Those already consuming a lycopene-rich Mediterranean-style diet may experience diminishing returns.

  • Genetic polymorphisms in BCO2 and SR-BI: Variants in beta-carotene oxygenase 2 (BCO2, an enzyme cleaving carotenoids) and scavenger receptor class B type 1 (SR-BI, a lipoprotein receptor involved in carotenoid uptake) modify circulating lycopene response to supplementation, with functional consequences for downstream antioxidant and signaling effects.

  • Sex-based differences: Some trials suggest a slightly larger lycopene-induced FMD improvement in men versus women, possibly mediated by differences in baseline endothelial function or testosterone-driven oxidative stress; data are not definitive.

  • Age: Older adults (typically 55+) show larger gains in endothelial parameters, plausibly because endothelial dysfunction is more advanced and there is more room for improvement.

  • Pre-existing health conditions: Type 2 diabetes, metabolic syndrome, and active oxidative stress states (e.g., chronic kidney disease) appear to amplify benefits on oxLDL and FMD endpoints. Stable hypertension is a positive predictor for blood-pressure response.

Potential Risks & Side Effects

A dedicated review of prescribing information is not applicable, as Cordiart is a food supplement; instead, the European Food Safety Authority opinions, post-marketing reports, and the safety literature on lycopene-rich tomato extracts and high-dose lycopene were reviewed.

Low 🟥

Mild Gastrointestinal Discomfort

Mild dyspepsia (indigestion or upper-abdominal discomfort), nausea, bloating, or loose stools have been reported infrequently, especially when Cordiart is taken on an empty stomach. The mechanism is non-specific irritation by the lipid-rich oleoresin matrix. Symptoms are typically transient and resolve with food co-administration or dose reduction.

Magnitude: Reported in approximately 1–5% of supplement users in clinical trials.

Skin Yellowing (Carotenodermia)

High intake of lycopene or other carotenoids can cause harmless yellow-orange discoloration of the skin, especially the palms and soles, due to lipophilic carotenoid deposition in the stratum corneum. The effect is reversible upon discontinuation. It is more likely at intakes exceeding 30 mg/day of lycopene.

Magnitude: Reported in less than 1% at typical Cordiart doses; more common at higher carotenoid intakes.

Speculative 🟨

Theoretical Pro-Oxidant Activity at Very High Doses

In vitro data suggest some carotenoids may exhibit pro-oxidant behavior under conditions of high oxygen partial pressure or in the presence of transition metals. The clinical relevance at typical Cordiart doses is unsupported, but caution is sometimes raised in heavy smokers given the historical CARET (Carotene and Retinol Efficacy Trial) and ATBC (Alpha-Tocopherol Beta-Carotene Cancer Prevention Study) trials of beta-carotene (a different carotenoid). No equivalent harm signal exists for lycopene supplementation.

Theoretical Increase in Bleeding Risk

Given the platelet-aggregation-modulating effect of related water-soluble tomato concentrates, a theoretical interaction with antiplatelet or anticoagulant therapy is sometimes raised. Clinical confirmation is lacking, and the lipophilic Cordiart matrix has weaker direct platelet effects than the water-soluble counterpart.

Reproductive Effects

Animal studies in rodents have explored high-dose lycopene exposure during pregnancy without definitive harm signals; human data during pregnancy are insufficient, and pregnant or lactating women are typically excluded from trials. Caution applies by precaution, not by evidence of harm.

Risk-Modifying Factors

  • Genetic polymorphisms: BCO2 (beta-carotene oxygenase 2, enzyme cleaving carotenoids) and CD36 (a lipid transporter) variants influence lycopene absorption and tissue accumulation, which may modulate both efficacy and the propensity for carotenodermia.

  • Baseline biomarkers: Pre-existing elevated bilirubin, hypothyroidism, or hepatic dysfunction may amplify carotenodermia risk because of overlapping mechanisms of skin pigmentation and reduced carotenoid clearance.

  • Sex-based differences: There are no clearly established sex-based differences in Cordiart’s risk profile. Women may be slightly more likely to notice cosmetic skin yellowing.

  • Pre-existing health conditions: Active gastrointestinal conditions (gastroesophageal reflux disease, irritable bowel syndrome) may be more sensitive to the lipid-rich oleoresin and require co-administration with a meal.

  • Age-related considerations: Older adults may have reduced bile acid output and somewhat lower carotenoid absorption, which generally decreases risk; concomitant polypharmacy (especially anticoagulants, antiplatelet agents) increases caution.

Key Interactions & Contraindications

  • Antiplatelet agents (aspirin, clopidogrel, ticagrelor): Theoretical additive antiplatelet effect, particularly with the water-soluble tomato concentrate lineage. Severity: caution. Clinical consequence: theoretical increase in bleeding risk; clinical confirmation lacking. Action: monitor for bruising/bleeding at standard doses; avoid combining without clinician oversight.

  • Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran): Theoretical additive effect on hemostasis. Severity: caution. Clinical consequence: theoretical bleeding risk. Action: monitor international normalized ratio (INR, a coagulation laboratory measure) more frequently when initiating Cordiart in warfarin users.

  • Antihypertensive medications (angiotensin-converting enzyme inhibitors / ACE inhibitors such as lisinopril; angiotensin receptor blockers / ARBs such as losartan; calcium channel blockers such as amlodipine; diuretics such as hydrochlorothiazide): Potential additive blood-pressure-lowering effect. Severity: monitor. Clinical consequence: hypotension (abnormally low blood pressure) and dizziness on dose stacking. Action: monitor home blood pressure when initiating.

  • Statins (atorvastatin, rosuvastatin): No documented pharmacokinetic interaction; potentially complementary on oxidized-LDL endpoints. Severity: none expected. Action: no specific change required.

  • Olestra and orlistat (lipase inhibitor): Reduce absorption of fat-soluble lycopene. Severity: monitor. Action: separate dosing by 2 hours.

  • Cholestyramine and bile-acid sequestrants: Reduce carotenoid absorption. Action: separate dosing.

  • Beta-carotene supplements: Compete for absorption pathways and may reduce lycopene uptake. Action: avoid stacking high-dose beta-carotene supplements.

  • OTC medications: Nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen) — theoretical additive effect on platelet function via different mechanism. Action: monitor for bruising; no contraindication.

  • Supplement interactions (additive blood pressure-lowering): Coenzyme Q10, beetroot/nitrate supplements, hibiscus, magnesium, omega-3 fatty acids — additive blood-pressure-lowering effect. Action: monitor home blood pressure.

  • Supplement interactions (additive antiplatelet): Fish oil at >2 g/day eicosapentaenoic acid plus docosahexaenoic acid (EPA/DHA), garlic extract, Ginkgo biloba, vitamin E at >400 IU/day. Action: monitor for bruising/bleeding when stacking.

  • Populations to avoid: Pregnant or lactating women (insufficient data, precaution only); patients within 7–14 days of major surgery (theoretical platelet effect, conservative practice); those with documented hypersensitivity to Solanum lycopersicum (tomato) or other Solanaceae family proteins; patients on therapeutic anticoagulation with INR > 3.0 or active bleeding diathesis (caution).

Risk Mitigation Strategies

  • Take with a fat-containing meal: Reduces gastrointestinal discomfort and improves carotenoid bioavailability through micellar incorporation, mitigating both side effect risk and dosing variability.

  • Start at the lowest labeled dose for 1–2 weeks: Low starting exposure (e.g., 1 capsule/day) before titrating to the full label dose limits the likelihood of gastrointestinal adverse events and allows tolerance assessment, mitigating dyspepsia and nausea risk.

  • Discontinue 7–14 days before scheduled surgery: A precautionary cessation interval addresses the theoretical antiplatelet effect, mitigating any speculative bleeding risk during invasive procedures.

  • Monitor home blood pressure when stacking with antihypertensives: Twice-daily home blood pressure measurement for the first 2–4 weeks after initiation, with a threshold for clinician review at systolic <100 mmHg or symptomatic hypotension, mitigates additive hypotension risk.

  • Confirm absence of tomato/Solanaceae allergy: Hypersensitivity screening through patient history avoids hypersensitivity reactions in atopic individuals (people with a genetic tendency to develop allergic conditions such as asthma, eczema, or hay fever).

  • Limit total dietary plus supplemental lycopene to under 30 mg/day: Bounded total carotenoid intake mitigates the cosmetic risk of carotenodermia and any speculative pro-oxidant effects at higher cumulative exposures.

  • Avoid stacking with high-dose vitamin E (>400 IU/day) or therapeutic-dose fish oil: Restricting concurrent antiplatelet-active supplements mitigates additive bleeding risk in those with cardiovascular comorbidities.

Therapeutic Protocol

The following protocol reflects the manufacturer’s standard label and the methodologies of clinical trials of standardized tomato extracts. Where evidence permits, alternative integrative-medicine approaches are noted.

  • Standard daily dose: One oral softgel per day with a fat-containing meal, providing approximately 7–15 mg of lycopene and the accompanying carotenoid matrix (phytoene, phytofluene, beta-carotene, tocopherols, phytosterols), as used in the LycoRed-sponsored Cambridge TomVasc trial (Cheriyan and colleagues, Cambridge University Hospitals NHS Foundation Trust) and related industry-supported studies.

  • Higher-dose protocol (used in some research settings): Two oral softgels per day, dividing the dose between morning and evening meals to maintain steady plasma carotenoid levels; reserved for adults with documented elevated cardiovascular risk under clinician supervision. The higher-dose protocol mirrors the dose levels used in the Cambridge TomVasc programme (Cheriyan et al., Cambridge University Hospitals NHS Foundation Trust), which evaluated standardized tomato extract in patients with established cardiovascular disease.

  • Best time of day: With the largest fat-containing meal of the day to maximize lipophilic absorption; whether morning or evening makes little practical difference given lycopene’s 2–3 day half-life.

  • Half-life and dose splitting: Lycopene’s elimination half-life of 2–3 days means single daily dosing produces relatively stable plasma concentrations after a 2–3 week run-in. Splitting the dose is not pharmacokinetically necessary but may be considered to limit gastrointestinal symptoms.

  • Genetic considerations: Adults known to carry BCO2 high-activity variants may metabolize lycopene more rapidly to apo-lycopenoids and may need the higher-dose protocol to achieve target plasma concentrations; CD36 variants influence absorption.

  • Sex-based differences: No formal sex-based dose differentiation. Some integrative practitioners note slightly larger response in men with established cardiovascular disease, but standard dosing applies.

  • Age-related considerations: Older adults (typically 65+) may benefit from co-administration with a moderate-fat meal due to reduced bile acid output, but no dose adjustment is standard.

  • Baseline biomarkers: Adults with elevated oxidized LDL, low circulating lycopene, or elevated high-sensitivity C-reactive protein (hs-CRP, a general inflammation marker) at baseline are most likely to show measurable biomarker response and may be reassessed at 12 weeks.

  • Pre-existing conditions: Adults with metabolic syndrome, type 2 diabetes, or stable hypertension have shown the largest endothelial-function gains in trials; stable, well-controlled cardiovascular disease is not a contraindication and may be a positive indication.

Discontinuation & Cycling

  • Intended duration: Cordiart is positioned as a long-term, daily intervention rather than a short course. Cardiovascular biomarker effects emerge over 4–12 weeks and require ongoing exposure to be maintained.

  • Withdrawal effects: No withdrawal syndrome has been described. Plasma lycopene declines over 2–4 weeks after cessation, and biomarker improvements (FMD, oxLDL) revert toward baseline over 4–8 weeks.

  • Tapering protocol: Not required; Cordiart can be discontinued abruptly without physiological rebound.

  • Cycling: Cycling is not standard practice and is not recommended on the basis of current evidence, since the desired effects depend on continuous exposure. Some integrative protocols rotate carotenoid sources (lycopene-rich, astaxanthin-rich, lutein-rich) over time to broaden the carotenoid spectrum, but evidence for rotation specifically benefiting cardiovascular endpoints is absent.

Sourcing and Quality

  • Origin and standardization: Cordiart sources its tomato extract from select cultivars grown for high carotenoid yield, typically processed into an oleoresin standardized to a defined lycopene content (approximately 6–15% by weight). Look for products that specify the lycopene content per capsule and confirm presence of the colorless carotenoids phytoene and phytofluene.

  • Third-party testing: Confirmed third-party testing (ISO 17025-accredited laboratories or equivalent) for carotenoid content, heavy metals, and pesticide residues is the marker of quality. Cordiart’s manufacturer-provided certificates of analysis should be available on request.

  • Excipient and form considerations: Soft-gel capsules using a lipid carrier (typically olive oil or medium-chain triglycerides) preserve carotenoid stability and improve bioavailability versus dry-blend tablets. Avoid products without a lipid carrier.

  • Storage: Carotenoids are sensitive to heat, light, and oxygen. Store in a cool, dark location; refrigeration is acceptable but not required.

  • Reputable alternatives: Where Cordiart is regionally unavailable, other standardized tomato oleoresin products from established suppliers — for example, Lyc-O-Mato (LycoRed; the underlying matrix that defines Cordiart’s chemotype) and Ateronon (Cambridge Nutraceuticals; the formulation used in the Cambridge TomVasc randomized trial) — provide comparable lycopene plus colorless carotenoid content and are reasonable substitutes. Products providing isolated lycopene without the broader matrix (commonly listed as “lycopene 10 mg” without phytoene/phytofluene/tocopherol declarations) may not produce the same clinical effects.

Practical Considerations

  • Time to effect: Plasma lycopene reaches steady state within 2–3 weeks. Endothelial and oxidative-stress biomarker improvements typically emerge by 8–12 weeks of continuous use; blood-pressure reductions, where they occur, follow a similar timeline.

  • Common pitfalls: Taking Cordiart on an empty stomach (reducing absorption), expecting rapid effects within days (carotenoid pharmacokinetics are slow), substituting purified lycopene at higher milligram doses (the matrix matters), and stacking many additive blood-pressure or antiplatelet supplements without monitoring.

  • Regulatory status: Cordiart is regulated as a food supplement in the European Union and is not a prescription medication. It is not approved by the United States Food and Drug Administration as a drug, though similar standardized tomato extract ingredients are available in the US dietary supplement category.

  • Cost and accessibility: Cordiart is moderately priced relative to other standardized phytoextracts, and is available primarily through European pharmacy channels and online retailers; access from outside Europe may require import or substitution with comparable standardized tomato extracts.

Interaction with Foundational Habits

  • Sleep: No direct interaction. The intervention does not affect sleep architecture, alertness, or melatonin pathways. Lycopene has been investigated in observational data for indirect cardiovascular benefits that may relate to sleep-disordered breathing risk, but no direct effect on sleep itself is documented.

  • Nutrition: Direct, potentiating interaction. Cordiart is best taken with a meal containing 5–15 g of fat for optimal lipophilic absorption; medium-chain or long-chain triglycerides both work. The intervention complements a Mediterranean-style or DASH (Dietary Approaches to Stop Hypertension) eating pattern, which already contains tomato-derived lycopene; the supplement is most useful for those with low baseline dietary lycopene. Cooked, oil-prepared tomato dishes are a natural dietary parallel.

  • Exercise: Indirect interaction. Aerobic and resistance training improve endothelial function via NO-dependent mechanisms that overlap with Cordiart’s proposed pathway; the combination may be additive on FMD and oxidative stress endpoints. Timing relative to workouts is not critical given lycopene’s slow pharmacokinetics; daily dosing is sufficient. No evidence of blunting of training adaptation has been described, in contrast to high-dose isolated antioxidants.

  • Stress management: Indirect interaction. Chronic psychological stress raises systemic oxidative stress and inflammatory tone (e.g., elevated hs-CRP), both of which Cordiart’s matrix may partly counter; conversely, effective stress management amplifies the cardiovascular signal of the intervention. No direct effect on cortisol or hypothalamic-pituitary-adrenal (HPA) axis function has been documented.

Monitoring Protocol & Defining Success

Baseline testing helps identify candidates most likely to benefit and provides reference values for assessing response over time.

  • Baseline labs and tests: A standard cardiovascular and metabolic baseline before initiation, including the biomarkers in the table below; optionally, plasma lycopene to identify those with low baseline carotenoid status.

Ongoing monitoring follows a cadence of baseline, 12 weeks, then every 6–12 months, aligned with the kinetics of biomarker response and the long-term nature of the intervention.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Systolic blood pressure 110–125 mmHg Primary cardiovascular endpoint sensitive to the intervention Home BP preferred; conventional reference up to 130 mmHg
Diastolic blood pressure 65–80 mmHg Secondary cardiovascular endpoint Conventional reference up to 85 mmHg
LDL cholesterol (LDL-C) <100 mg/dL (low risk); <70 mg/dL (CVD) Primary atherogenic lipid; modest response to intervention Fasting preferred; conventional reference <130 mg/dL
Oxidized LDL (oxLDL) <60 U/L Direct molecular marker of LDL oxidation, the most sensitive biomarker for this intervention Specialty test; not in standard panels; fasting preferred
High-sensitivity C-reactive protein (hs-CRP) <1.0 mg/L Systemic inflammation marker; indirect benefit pathway Avoid testing during acute illness
Plasma lycopene >0.5 µmol/L Confirms supplementation adherence and absorption Specialty test; useful for non-responder workup
Flow-mediated dilation (FMD) >7% Functional endothelial endpoint; the most direct measure of vascular response Specialized vascular ultrasound; not widely available outside research settings
Triglycerides <100 mg/dL Metabolic and cardiovascular risk marker Fasting required; conventional reference <150 mg/dL
Fasting glucose 75–90 mg/dL Metabolic baseline; some evidence of modest improvement with carotenoid intake Fasting required; conventional reference <100 mg/dL

Qualitative markers complement laboratory monitoring and reflect day-to-day cardiovascular and general wellness:

  • Subjective energy and exertion tolerance during routine activity
  • Frequency and severity of headache or dizziness (markers of blood-pressure stability)
  • Skin appearance for early carotenodermia (palms, soles)
  • Gastrointestinal tolerance (frequency of dyspepsia or bloating)
  • Sleep quality, as a general health proxy
  • Cognitive clarity and focus, as general health markers

Emerging Research

  • Vascular effects of standardized tomato extract: A randomized clinical trial registered as NCT01100385 (TomVasc — Vascular Effects of Tomato Extract) investigated standardized tomato extract effects on vascular function in adults with ischemic heart disease, transient ischemic attack, stroke, and peripheral vascular disease (n=72). Primary endpoint included change in flow-mediated dilation.

  • Antiplatelet effects in hypertensive subjects: A phase IV trial registered as NCT03206944 evaluated standardized tomato extract on platelet aggregation and related cardiovascular markers in hypertensive subjects (n=82). Primary endpoint addressed antiplatelet effect quantification.

  • Tomato pomace extract on platelet aggregation: A randomized trial registered as NCT02986165 examined the effect of ingesting a tomato pomace extract on platelet aggregation in apparently healthy young men (n=99, ages 18-26). The trial provides comparative dose-response data on whole-matrix extracts versus placebo.

  • Open question on cardiovascular event endpoints: No registered trial has been adequately powered to test whether standardized tomato extract supplementation reduces hard cardiovascular endpoints (myocardial infarction, stroke, cardiovascular mortality). The field would require an event-driven RCT in a high-risk population, which is unlikely to be funded for a non-patentable food supplement.

  • Mechanistic refinement on phytoene and phytofluene: Foundational work by Engelmann et al., 2011 reviews the nutritional aspects of phytoene and phytofluene as carotenoid precursors to lycopene, supporting the rationale for whole-extract products like Cordiart over purified lycopene; human trials of isolated phytoene/phytofluene remain absent.

  • Recent endothelial-function evidence: A 2025 RCT (Yoshida et al., 2025) reported improvement of vascular endothelial function with intake of lycopene-rich tomato juice in healthy adults, providing additional evidence that the cardiovascular signal can extend beyond high-risk populations under specific intake conditions. Further trials are needed to stratify response by baseline endothelial function.

Conclusion

Cordiart is a standardized tomato extract food supplement combining lycopene with phytoene, phytofluene, beta-carotene, tocopherols, and phytosterols, positioned as a cardiovascular and metabolic support intervention for health- and longevity-oriented adults. The evidence base centers on improvements in endothelial function and reductions in oxidized low-density lipoprotein, with a smaller and less consistent signal on systolic blood pressure and modest impact on cholesterol. Effects are most reproducible in adults with established cardiovascular risk factors and are smaller or absent in healthy normotensive populations.

The intervention has a favorable safety profile, with infrequent mild gastrointestinal effects and the cosmetic possibility of skin yellowing at higher cumulative carotenoid intakes. Theoretical interactions with antiplatelet, anticoagulant, and antihypertensive medications warrant attention, particularly in those already managing cardiovascular conditions.

Much of the evidence relies on surrogate endpoints rather than hard cardiovascular events, which leaves meaningful uncertainty about long-term clinical impact. Some of the supporting research has been sponsored by, or used material from, the ingredient manufacturer LycoRed (developer of the Lyc-O-Mato matrix underlying Cordiart), a financial conflict of interest noted by independent reviewers. For health- and longevity-oriented adults, Cordiart represents a low-risk addition to a broader Mediterranean-pattern diet, exercise, and stress-management approach, with the strongest rationale in those with elevated cardiovascular risk and low baseline dietary lycopene exposure.

Top - Benefits - Risks - Protocol